BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 30362586)

  • 1. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Sommermeyer D; Hill T; Shamah SM; Salter AI; Chen Y; Mohler KM; Riddell SR
    Leukemia; 2017 Oct; 31(10):2191-2199. PubMed ID: 28202953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells.
    Dwivedi A; Karulkar A; Ghosh S; Srinivasan S; Kumbhar BV; Jaiswal AK; Kizhakeyil A; Asija S; Rafiq A; Kumar S; Nisar A; Patil DP; Poojary MV; Jain H; Banavali SD; Highfill SL; Stroncek DF; Shah NN; Fry TJ; Narula G; Purwar R
    Mol Cancer Ther; 2021 May; 20(5):846-858. PubMed ID: 33632869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
    Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
    J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.
    Fallah-Mehrjardi K; Mirzaei HR; Masoumi E; Jafarzadeh L; Rostamian H; Khakpoor-Koosheh M; Alishah K; Noorbakhsh F; Hadjati J
    Immunol Lett; 2020 Jul; 223():44-52. PubMed ID: 32289340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.
    De Oliveira SN; Wang J; Ryan C; Morrison SL; Kohn DB; Hollis RP
    J Transl Med; 2013 Jan; 11():23. PubMed ID: 23360526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
    Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
    Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
    Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
    Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA
    Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
    Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
    Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.